Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors
Zeynep Ozturk Yalcin, Arda Erdut, Guldehan Haberal, Mustafa Arici, Aygin Bayraktar-Ekincioglu · 2026
Read Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitors by Zeynep Ozturk Yalcin, Arda Erdut, Guldehan Haberal, Mustafa Arici, Aygin Bayraktar-Ekincioglu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13292308.txt.
Description
Zeynep Ozturk Yalcin and co-authors audit a 2026 clinic question: how much kidney-toxic medication baggage do chronic kidney disease patients carry when starting SGLT2 inhibitors? The observational study ran in a university nephrology clinic from September 2022 to February 2023. A clinical pharmacist reviewed the medicines of 72 newly prescribed patients, scoring drug problems and nephrotoxic load.
The review found 69 drug-related problems, led by wrong treatment duration, drugs without an indication, and untreated symptoms. Doctors accepted 85.5 percent of the pharmacist's recommendations. Patients took a median of two nephrotoxic drugs each, yet no overt toxic events surfaced, and burden did not track with estimated kidney failure risk. The authors present real-world baseline data and ask for prospective studies of pharmacist review.
Catalog record
| CREATOR | Zeynep Ozturk Yalcin, Arda Erdut, Guldehan Haberal, Mustafa Arici, Aygin Bayraktar-Ekincioglu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34714 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |